Patents by Inventor Haig AGHAJANIAN

Haig AGHAJANIAN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions and Methods for Treating Heart Disease via Redirected T Cell Immunotherapies
    Publication number: 20240016848
    Abstract: The present invention includes compositions and methods for treating heart disease and/or heart failure. In one embodiment, the treatment includes administering to the subject a cell genetically modified to express a chimeric antigen receptor (CAR), comprising an antigen binding domain specific for fibroblast activation protein (FAP). In another embodiment, the treatment includes administering a cell genetically modified to express a T cell receptor (TCR) specific for an activated fibroblast.
    Type: Application
    Filed: September 6, 2023
    Publication date: January 18, 2024
    Inventors: Jonathan Epstein, Haig Aghajanian, Steven M. Albelda, Ellen Puré
  • Methods for treating heart disease via redirected T cell immunotherapies
    Patent number: 11786551
    Abstract: The present invention includes compositions and methods for treating heart disease and/or heart failure. In one embodiment, the treatment includes administering to the subject a cell genetically modified to express a chimeric antigen receptor (CAR), comprising an antigen binding domain specific for fibroblast activation protein (FAP). In another embodiment, the treatment includes administering a cell genetically modified to express a T cell receptor (TCR) specific for an activated fibroblast.
    Type: Grant
    Filed: September 25, 2018
    Date of Patent: October 17, 2023
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Jonathan Epstein, Haig Aghajanian, Steven M. Albelda, Ellen Puré
  • In vivo targeting of Fibrosis by anti-CD5-targeted FAP-CAR T mRNA-LNP
    Publication number: 20230203538
    Abstract: The present invention relates to compositions and methods for T cell targeted delivery of nucleoside modified mRNA molecules encoding agents for the treatment and prevention of fibrosis, cardiac disease, and diseases and disorders associated therewith.
    Type: Application
    Filed: October 7, 2022
    Publication date: June 29, 2023
    Inventors: Hamideh Parhiz, Drew Weissman, Jonathan Epstein, Istvan Tombacz, Joel Rurik, Haig Aghajanian
  • Compositions and Methods for Treating Heart Disease via Redirected T Cell Immunotherapies
    Publication number: 20200268796
    Abstract: The present invention includes compositions and methods for treating heart disease and/or heart failure. In one embodiment, the treatment includes administering to the subject a cell genetically modified to express a chimeric antigen receptor (CAR), comprising an antigen binding domain specific for fibroblast activation protein (FAP). In another embodiment, the treatment includes administering a cell genetically modified to express a T cell receptor (TCR) specific for an activated fibroblast.
    Type: Application
    Filed: September 25, 2018
    Publication date: August 27, 2020
    Inventors: Jonathan EPSTEIN, Haig AGHAJANIAN